Combination of sunitinib and 177Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer

Combination of sunitinib and 177Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer

Sunitinib is an effective treatment for patients with metastatic Renal Cell Carcinoma (mRCC) but ultimately resistance occurs. The aim of this study was to investigate sunitinib resistance in RCCs and to develop therapeutic combination strategies with targeted radioimmunotherapy (RIT).We studied two...

Full description

Bibliographic Details
Main Authors: Jeannette C. Oosterwijk-Wakka, Mirjam C.A. de Weijert, Gerben M. Franssen, Dimitar R. Kolev, Ton A.F.J. de Haan, Otto C. Boerman, Peter F.A. Mulders, Egbert Oosterwijk
Format: Article
Language:English
Published: Elsevier 2022-10-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Sunitinib
RCC
Combination therapy
CAIX-targeted radioimmunotherapy
[177Lu]Lu-cG250 RIT
Sunitinib resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558622000537

Internet

http://www.sciencedirect.com/science/article/pii/S1476558622000537

Similar Items